Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Amgen, Servier take options to each other's cardiovascular compounds; deal terminated

Executive Summary

Amgen Inc. has licensed US rights to Servier SA’s ivabradine, an If inhibitor that is sold in the EU and over 100 countries across the globe as Procoralan for chronic heart failure and stable angina in patients experiencing increased heart rates.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • Product or Technology Swap
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register